title: High-dose VP16 cisplatinum in soft tissue sarcoma of children.
abstract: Nine children with soft tissue sarcomas, five of them rhabdomyosarcomas with initial metastatic disease, (one patient, partial response, one patient), refractory primary, (two patients, relapse, five patients) were treated with a combination of high-dose VP16 (100 mg/m2 daily for 5 days) and cisplatin (40 mg/m2 daily for 5 days). The response rate was five out of nine or 55% (+/- 32%) (two complete and three partial, responses). Three of the five responders had rhabdomyosarcomas. The duration of response was 4-58 months (median 11 months). The toxicity was mainly hematological. Thus, the high-dose VP16-cisplatin association warrants further evaluation in soft tissue sarcoma in children.
authors.affiliation: Pediatric Department of Centre Leon Berard, Lyon, France.
authors.forename: M
authors.initials: M
authors.lastname: Grabois
authors.forename: D
authors.initials: D
authors.lastname: Frappaz
authors.forename: E
authors.initials: E
authors.lastname: Bouffet
authors.forename: C
authors.initials: C
authors.lastname: Carrie
authors.forename: D
authors.initials: D
authors.lastname: Bouhour
authors.forename: T
authors.initials: T
authors.lastname: Philip
authors.forename: M
authors.initials: M
authors.lastname: Brunat-Mentigny
mesh_terms: D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D002945:Cisplatin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D012509:Sarcoma / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D005047:Etoposide; D002945:Cisplatin